

Rev. 4/14/82

Toxicology Branch/HE

D-7660

6-21-82

Caswell No(s): 82-MA-03 528

To: Don Stubbs, P#41, Registration Division, OPP.

Registration No(s): 82-MA-03

Pesticide Petition No(s): not applicable

Chemical(s): LOROX 50WP a.i. = linuron, chem. name = 3-(3,4-Dichlorophenyl)-1-methoxy-1-methylurea

EPA Reg. No. 352-270

Requested Action(s): Section 18 request by the State of Mass. to apply Lorox 50WP on dry bulb onions at the maximum rate of 1.0 lb./acre on 300 acres in order to prevent weed growth e.g. Galinsoga and other broad leaf annual weeds.

Recommendation: TOX recommends for the present requested use of Lorox 50WP in onion fields (300 acres total) in the State of Massachusetts, 1982 growing season.

Inert(s) cleared 180.1001: yes

% of ADI occupied: Existing: 90.05 % Resulting: 91.71%

Resulting % increase in TMRC: 1.67%, a level of increase TOX considers not significant ^{at present} in risk.

Data considered in setting the ADI: Dog Study (M. Quaife, 1963) re-reviewed May, 1982-O.K.

Dog NOEL = 25 ppm in the diet (= 0.625 mg/kg) using a safety factor = 100. ADI = .0063 mg/kg MPI = .3750 mg/day

Attached (?): ADI printout: YES/NO; TOX "one-liner": YES/NO; DER: YES/NO

Existing regulatory actions against registration: RPAR being considered on basis of rat benign testicular tumors (1980, Haskell Lab)

RPAR status: uncertain--B. Dykstra recommended for RPAR review May 16, 1980--no action yet.

New Data: No new data submitted with this Sec. 18 request. All data being reviewed by now June 1982 in the reregistration process. Conclusions of 2-yr. rat study observing testicular tumors re-verified by J. holder (TOX) and Mitre Corp. on contract.

Data gaps: no gaps exist affecting the present request by the State of Mass.

Comments: Action level set by RCB (E. Zager) of 0.5ppm in/on dry bulb onions. Max. contribution for the anticipated use is 0.006225 mg/day for an average individual consuming a total dietary intake of 1.5 kg/day. Food factor for onions = 0.83%. Old TMRC = .3377 mg/day + .006225 mg/day contribution = new IMRC 0.3439 mg/day which is 91.71 % of MPI of .3750 mg/day. Careful consideration should be made toward any further granting use of Linuron due to the high percentage of MPI in current use and the testicular onco. trigger which has been recommended to SPRD for Special Review.

Reviewer: (James) H. Zager, Ph.D.

Date: 6/18/82

JUN 21 1982